, , ,

<<


 >>  ()
Pages:     | 1 | 2 ||

() VEGF ...

-- [ 3 ] --

62. Kindler HL, Friberg G, Stadler WM, et al. Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advancedpancreatic cancer (PC): updated results of a multi center phase II trial. J Clin Oncol 2004;

22(July 15 Suppl.):

Abstract4009.

63. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastaticcolorectal cancer. N Engl J Med 2004;

350:233542.

64. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab pluscapecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;

23:7929.

65. Fyfe GA, Hurwitz H, Fehrenbacher L, et al. Bevacizumab plus irinotecan/5 FU/leucovorin for treatment of metastaticcolorectal cancer results in survival benefit in all pre specified patient subgroups. J Clin Oncol 2004;

22(July Suppl.):Abstract 3617.

66. Koeppen H, Ince W, Holmgren E, et al. Molecular tumor characteristics and response to bevacizumab plus irinotecan/5 fluorouracil/leucovorin in metastatic colorectal cancer. Eur J Cancer Suppl 2004;

2:48 (Abstract 150).

67.Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves withthe availability of fluorouracil leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;

22:120914.

68. Kabbinavar FF, Schulz J, McCleod M, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor)to prolong progression free survival in first line colorectal cancer (CRC) in subjects who are not suitable candidates forfirst line CPT 11. J Clin Oncol 2004;

22(July 15 Suppl.): Abstract 3516.

69. Mass RD, Fyfe G, Hambleton J, et al. Bevacizumab in combination with 5 FU/leucovorin improves survival in patientswith metastatic colorectal cancer: a combined analysis. J Clin Oncol 2004;

22(July 15 Suppl.): Abstract 3616.

70. Novotny WF, Holmgren E, Nelson B, Mass R, Kabbinavar F, Hurwitz H. Bevacizumab (a monoclonal antibody tovascular endothelial growth factor) does not increase the incidence of venous thromboembolism when added to first line chemotherapy to treat metastatic colorectal cancer. J Clin Oncol 2004;

22(July 15 Suppl.): Abstract 3529.

71. Langmuir VK, Cobleigh MA, Herbst RS, et al. Successful long term therapy with bevacizumab (Avastin) in solid tumors.Proc Am Soc Clin Oncol 2002;

21 (Abstract 32).

72. Hambleton J, Novotny WF, Hurwitz H, et al. Bevacizumab does not increase bleeding in patients with metastaticcolorectal cancer receiving concurrent anticoagulation. J Clin Oncol 2004;

22(July 15 Suppl.): Abstract 3528.

73. Scappaticci F, Fehrenbacher L, Cartwright T, et al. Analysis of wound healing and bleeding post surgery in metastaticcolorectal cancer patients treated with bevacizumab. Presented at: 2004 Gastrointestinal Cancers Symposium;

2224 January 2004;

San Francisco, Ca. Abstract 235. Available at: http://www.asco.org. Accessed 16 November 2004.

74. Hochster H, Welles, L, Hart R, et al. Bevacizumab (B) with oxaliplatin (O) based chemotherapy in the first line therapyof metastatic colorectal cancer (mCRC): preliminary results of the randomized TREE 2 trial. Presented at:

2005Gastrointestinal Cancers Symposium;

2729 January 2005;

Hollywood, Fl. Abstract 241. Available at:http://www.asco.org. Accessed 15 February 2005.

75. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High dose bevacizumab in combination with FOLFOX4 improves survivalin patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group(ECOG) study E3200. Presented at: 2005 Gastrointestinal Cancers Symposium;

2729 January 2005;

Hollywood, Fl.Abstract 169a. Available at: http://www.asco.org. Accessed 15 February 2005.

76. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine pluscisplatin in the treatment of patients with advanced non small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;

19:32108.

77. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non small celllung cancer. N Engl J Med 2002;

346:928.

78. Bukowski RM. Immunotherapy in renal cell carcinoma. Oncology (Huntingt) 1999;

13:80110.

79. Sternberg CN. Metastatic renal cell cancer treatments. Drugs Today (Barc) 2003;

39(Suppl. C):3959.

80. Sano T, Horiguchi H. Von Hippel Lindau disease. Microsc Res Tech 2003;

60:15964.

81. Wiesener MS, Munchenhagen PM, Berger I, et al. Constitutive activation of hypoxia inducible genes related tooverexpression of hypoxia inducible factor 1alpha in clear cell renal carcinomas. Cancer Res 2001;

61:521522.

82. Jacobsen J, Grankvist K, Rasmuson T, Bergh A, Landberg G, Ljungberg B. Expression of vascular endothelial growthfactor protein in human renal cell carcinoma. BJU Int 2004;

93:297302.

83. Yang JC. Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res 2004;

10:6367S70S.

84. Hainsworth JD, Sosman JA, Spigel DR, et al. Phase II trial of bevacizumab and erlotinib in patients with metastatic renalcarcinoma (RCC). J Clin Oncol 2004;

23:22(July 15 Suppl.): Abstract 4502.

85. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib improves survival when added to gemcitabine in patients withadvanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC CTG]. Presented at: 2005 Gastrointestinal Cancers Symposium;

2729 January 2005;

Hollywood, Fl. Abstract 77.Available at: http://www.asco.org. Accessed 15 February 2005.

86. Karayiannakis AJ, Bolanaki H, Syrigos KN, et al. Serum vascular endothelial growth factor levels in pancreatic cancerpatients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett 2003;

194:11924.

87. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K. High expression of vascular endothelial growth factor isassociated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma.

Cancer2000;

88:223945.

88. Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first linetherapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;

15:240313.

89. Miller KD, Rugo HS, Cobleigh MA, et al. Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastin) versuscapecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and ataxane. Breast Cancer Res Treat 2002;

79 (Abstract 36).

90. Relf M, LeJeune S, Scott PAE, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic andbasic fibroblast growth factor, tumor growth factor b 1, platelet derived endothelial cell growth factor, placenta growthfactor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;

57: 9639.

. .

, 125445, , . , 24

.: (095) 258 : (095) 258 www.roche.ru

Pages:     | 1 | 2 ||
 
 >>  ()





 
<<     |    
2013 www.libed.ru - -

, .
, , , , 1-2 .